WT | News

Discover our incredible news!

News

X
Text dummy
Text Link

Neuralink Implants Brain Chip in Human

Neuralink announced on Sunday that the first human patient had gotten an implant and was doing well.

The first human patient has received an implant from brain-chip startup Neuralink on Sunday and is recovering well, the company's billionaire founder Elon Musk said.

The identity of the study's first human patients have not been made public, but the initial "Prime" study's participants had to be over 22, quadriplegic from spinal cord injuries or ALS, free of any history of seizures, active implants like pacemakers, or scheduled MRI scans.

"Initial results show promising neuron spike detection," Musk said in a post on the social media platform X on Monday.
Spikes are activity by neurons, which the National Institute of Health describes as cells that use electrical and chemical signals to send information around the brain and to the body.

Musk stated four and a half years ago that Neuralink intended to have its first human implants placed by a machine by the end of 2020. After accounting for Musk's well-known exuberance when it comes to deadlines, the company has delivered almost on schedule.

After enduring a barrage of criticism regarding its treatment of animals following a Reuters report that included testimony from current and former employees as well as leaked internal documents to disclose over 1,500 animal deaths and excessive, needless cruelty at the startup, Neuralink finally received FDA approval last year.

In September, Neuralink said it received approval for recruitment for the human trial.

According to a recent statement from Neuralink, the project employs a robot to surgically implant a brain-computer interface (BCI) implant in a part of the brain that governs the intention to move. Its primary objective is to allow people to operate a computer cursor or keyboard with just their thoughts, reports Reuters.

The implants' "ultra-fine" threads help transmit signals in participants' brains, Neuralink has said.

The first product from Neuralink would be called Telepathy, Musk said in a separate post on X.

In order to assess the safety of the implant and surgical robot, the business is conducting a study for its wireless brain-computer interface called PRIME Study.

The business has been under pressure to examine its safety procedures. The U.S. Department of Transportation (DOT) punished the corporation for breaking regulations pertaining to the transportation of hazardous commodities, according to a Reuters article earlier this month.

Related Elon Musk’s Neuralink Raises $280 Million

The company was estimated to be worth $5 billion in June of last year. However, veterinary records revealed problems with the implants on monkeys, including paralysis, seizures, and brain swelling. In late November, four lawmakers asked the U.S. Securities and Exchange Commission to look into whether Musk had misled investors about the safety of its technology.

Musk wrote in a social media post on Sept. 10 that "no monkey has died as a result of a Neuralink implant." He added that the company chose "terminal" monkeys to minimize risk to healthy ones.

Text Link

A Toddler Teaches Language to Artificial Intelligence

An artificial intelligence (AI) that was trained to recognize English using a toddler’s recordings.

AI systems, such as GPT-4, can now learn and use human language, but they learn from astronomical amounts of language input—much more than children receive when learning how to understand and speak a language. The best AI systems train on text with a word count in the trillions, whereas children receive just millions per year.

Due to this enormous data gap, researchers have been skeptical that recent AI advances can tell us much about human learning and development. An ideal test for demonstrating a connection would involve training an AI model, not on massive data from the web, but on only the input that a single child receives. What would the model be able to learn then?  

A team of New York University researchers ran this exact experiment. They trained a multimodal AI system through the eyes and ears of a single child, using headcam video recordings from when the child was six months and through their second birthday. They examined if the AI model could learn words and concepts present in a child’s everyday experience.

Their findings, reported in the latest issue of the journal Science, showed that the model, or neural network, could, in fact, learn a substantial number of words and concepts using limited slices of what the child experienced. That is, the video only captured about 1% of the child’s waking hours, but that was sufficient for genuine language learning.

“We show, for the first time, that a neural network trained on this developmentally realistic input from a single child can learn to link words to their visual counterparts,” says Wai Keen Vong, a research scientist at NYU’s Center for Data Science and the paper’s first author. “Our results demonstrate how recent algorithmic advances paired with one child’s naturalistic experience has the potential to reshape our understanding of early language and concept acquisition.”

“By using AI models to study the real language-learning problem faced by children, we can address classic debates about what ingredients children need to learn words—whether they need language-specific biases, innate knowledge, or just associative learning to get going,” adds Brenden Lake, an assistant professor in NYU’s Center for Data Science and Department of Psychology and the paper’s senior author. “It seems we can get more with just learning than commonly thought.”

Related Ways AI Will Be Used in Healthcare in 2024

Vong, Lake, and their NYU colleagues, Wentao Wang and Emin Orhan, analyzed a child’s learning process captured on first-person video—via a light, head-mounted camera—on a weekly basis beginning at six months and through 25 months, using more than 60 hours of footage. The footage contained approximately a quarter of a million-word instances (i.e., the number of words communicated, many of them repeatedly) that are linked with video frames of what the child saw when those words were spoken and included a wide range of different activities across development, including mealtimes, reading books, and the child playing.

NYU researchers analyzed a child’s learning process captured on first-person video—via a light, head-mounted camera and trained a multimodal AI system through the eyes and ears of a single child. Video by Jonathan King/NYU's Office of Public Affairs.

The NYU researchers then trained a multimodal neural network with two separate modules: one that takes in single video frames (the vision encoder) and another that takes in the transcribed child-directed speech (the language encoder). These two encoders were combined and trained using an algorithm called contrastive learning, which aims to learn useful input features and their cross-modal associations. For instance, when a parent says something in view of the child, it is likely that some of the words used are likely referring to something that the child can see, meaning comprehension is instilled by linking visual and linguistic cues.

“This provides the model a clue as to which words should be associated with which objects,” explains Vong. “Combining these cues is what enables contrastive learning to gradually determine which words belong with which visuals and to capture the learning of a child’s first words.”

After training the model, the researchers tested it using the same kinds of evaluations used to measure word learning in infants—presenting the model with the target word and an array of four different image options and asking it to select the image that matches the target word. Their results showed that the model was able to learn a substantial number of the words and concepts present in the child’s everyday experience. Furthermore, for some of the words the model learned, it could generalize them to very different visual instances than those seen at training, reflecting an aspect of generalization also seen in children when they are tested in the lab.

“These findings suggest that this aspect of word learning is feasible from the kind of naturalistic data that children receive while using relatively generic learning mechanisms such as those found in neural networks,” observes Lake.

Text Link

Hyprshell Combines Robotics and Ergonomics with AI

The Hypershell Omega aims to decrease backpack weight, enhance natural range.

A product line aimed at producing a new breed of superhuman outdoor adventurer is set to emerge from one of the most bizarre Kickstarter ideas of 2023. In order to reduce backpack weight, increase natural range, and facilitate travel, the Hypershell Omega burst onto the Kickstarter scene in March of last year. It is a wearable set of artificial intelligence (AI)-driven robotic legs that promises to offer man the strength of a horse in high-alpine situations. After a $1 million US success story with the campaign, the Chinese business is getting ready to present its two most recent improvements at CES 2024.

Because Hypershell is an anomaly in the exoskeleton space, it jumps out of the page right away. Hypershell is essentially trying to cut the cord on exoskeleton technology and release its robo legs into a highly variable and unpredictable wilderness environment. Most exoskeletons that we've seen over the years are designed to perform basic, repetitive activities in a business or everyday context. Hypershell also aims to assist mountaineers in reaching summits, trekkers in extending their hikes, and trail runners in enjoying quicker, smoother runs across challenging terrain, instead of restricting itself to basic, one-time activities like short, level walks, reports New Atlas.

When the Hypershell Omega originally surfaced on Kickstarter, it seemed a bit unrealistic, so we were a little taken aback when it eventually drew over 2,000 backers who pledged over $HK9 million (about $1.2 million). Although Hypershell hasn't quite left the vaporware stage yet, based on the campaign's comments section, those backers are still waiting for their genuine exoskeletons. Nevertheless, Hypershell has been making adjustments, delivering its exoskeleton, and giving updates on its development.

At the official opening of CES on Tuesday, January 9, Hypershell will showcase its most recent improvements, regardless of when the first adventure exos become available to backers. The ProX and the GoX, two distinct Mountain Exoskeleton versions, will be displayed by Hypershell.

Hypershell has not yet released the GoX's specifications, but it has stated that the ProX would resemble the Omega prototype it unveiled during its Kickstarter campaign in terms of specs. With one powered and eight passive joints, the all-terrain ProX wearable—designed for runners, long-distance hikers, and other outdoor enthusiasts—can channel up to 800 watts (1 hp) of motor power into the adventurer's legs. It will counterbalance up to 66 lb (30 kg) of weight, such as that carried in a backpack, and lessen the physical strain of hiking and climbing in mountainous terrain.

Related Exoskeleton Product Finder Launch in Beta Version

The ProX will be able to more accurately anticipate and adjust to each user's unique movements thanks to Hypershell's AI engine. When not in use, the 4.4-lb (2-kg) waist-mounted gadget may be easily carried by folding down and attaching to a backpack. It has IP54 weatherproofing and can operate in as low as -20 ° (-4 °F).

With the addition of a larger battery, Hypershell has increased the range of its exoskeleton to up to 22 miles (35 km) since its original Kickstarter launch last year. The most recent Hypershell photos reveal the inclusion of discs on the upper legs and a larger hardware box on the back of the device.

The Mountain Exoskeletons are currently advertised at $599 to $1,299 preorder pricing on Hypershell's website.

Text Link

Low Bone Density Treating Wearable Gets FDA Clearance

Bone Health Technologies received FDA clearance for Osteoboost.

Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for Osteoboost, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia (low bone density).

Osteoboost is a wearable belt device, worn on the hips, that delivers targeted, calibrated vibration to the lumbar spine and hips. Osteoboost is indicated to reduce bone strength and density decline in postmenopausal women and is the first and only solution specifically designed to improve bone health during osteopenia. This breakthrough technologyis safe, medication-free, and easy to use at home, making it suitable for a wide variety of patients with bone densityloss.

An estimated 52 million Americans have osteopenia, the precursor to osteoporosis, driving an addressable market of over $30B in the U.S. and $100B globally. Half of all women suffer from fractures during their lifetime, and most of these fractures occur during the osteopenia stage.

“Today’s groundbreaking decision represents the first non-pharmacological therapy approved to treat this widespread and serious condition. With Osteoboost, we have a new treatment option — free of serious adverse events — that taps into the body’s natural mechanism to stimulate bone growth,” said Laura Yecies, CEO of Bone Health Technologies. “Women’s health has been underserved for too long, making this a huge stepforward for older women who have lacked effective treatment options and are seeking an effective way to protect their bone health.”

Osteoboost was reviewed through the FDA’s De Novo classification process and received Breakthrough Device Designation.The Osteoboost clearance creates an entirely new class of therapeutics for low bone density outside of pharmacological intervention. Notably, Osteoboost also represents the first therapeutic mechanism specifically designed and cleared for intervention during the osteopenia stage. Until now, patients with osteopenia have lacked effective therapeutic options. Before Osteoboost, the standard of care for osteopenia focused on regular weight-bearing exercise and calcium supplementation — neither of which have been proven to significantly slow the loss of bone density.

Related New Wearable Treats Ankle Arthritis

“There are millions of American women with low bone density or osteopenia. This is often the precursor to osteoporosis. We have little to offer those women other than calcium and vitamin D supplements,” said David B. Karpf, MD, Adjunct Clinical Professor of Endocrinology, Gerontology & Metabolism, Stanford University School of Medicine and attending in the Osteoporosis & Metabolic Bone Disease Clinic. “The field of bone health right now is missing innovative approaches — there are no new agents in clinical trials for osteoporosis and nothing for women who have osteopenia. With the aging of our population, we need new ways to effectively prevent the decline in bone mass and strength that affects all women in the peri-menopause or post-menopausal stage.”

Osteoboost was granted clearance based on data from an NIH-funded double-blinded, sham-controlled study conducted at the University of Nebraska Medical Center. The data, which were shared at the 2023 ENDO and ASBR conferences, demonstrate the efficacy of Osteoboost in directly stimulating bone growth and preserving bone mineral density and strength by sending low-frequency vibrations directly to the lumbar spine and hips.  

The primary outcome measurement was the change in vertebral strength measured by CT scan. Per Protocol (PP) — subjects (those who used the device a minimum of 3 times per week) in the Active Treatment group lost, on average, 0.48% bone strength, while those in the Sham group lost 2.84%, with a relative difference of 2.36% (P=0.014). Additionally, CT measurement of vertebral bone density was conducted and showed a 1.68% relative benefit for those using the Osteoboost (P=0.008). These results represent a dramatic reduction in the loss of bone strength and density. Zero serious adverse events were reported.

“The well-being and ability of postmenopausal women to maintain an active lifestyle is threatened when loss of estrogen causes rapid loss of bone,” said Laura Bilek, Ph.D., Associate Dean for Research and Associate Professor at the University of Nebraska and principal investigator for this study. “Although lifestyle interventions such as exercise and diet are beneficial to bone, the effect is small. The Osteoboost shows promise in slowing the loss of bone density and strength and may fill the treatment gap.”

About Bone Health Technologies

Bone Health Technologies (BHT) is a Redwood City-based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and associated bone fractures. The company’s first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating post-menopausal osteopenia. BHT is backed by leading investors, including Esplanade Ventures, Ambit Health Ventures, Good Growth Capital, Portfolia, Astia Angels, and Golden Seeds.

Text Link

The Potential of 3D Printed Electronic Skin

Researchers at Texas A&M University have created a 3D-printed electronic skin.

Human skin has over 1,000 nerve endings, making it the brain's greatest sensory organ connected to the externalen vironment. Touch, pressure, and temperature all provide a variety of feedback. Skin is an essential organ because of its intricate properties, which also make it difficult to reproduce.

A 3D-printed electronic skin (E-skin) that can stretch, flex, and sense like human skin has been created by Texas A&M University researchers using nano engineered hydrogels that have programmable electrical and thermal biosensing capabilities.

“The ability to replicate the sense of touch and integrate it into various technologies opens up new possibilities for human-machine interaction and advanced sensory experiences,” said Dr. Akhilesh Gaharwar, professor and director of research for the Department of Biomedical Engineering. “It can potentially revolutionize industries and improve the quality of life for individuals with disabilities.”

The E-skin will have a wide range of applications in the future, such as wearable medical devices that continuously track vital signs like blood pressure, heart rate, mobility, and temperature. These gadgets will also give users feedback and assist them in developing better motor skills and coordination, reports Printed Electronics.

“The inspiration behind developing E-skinis rooted in the desire to create more advanced and versatile interfaces between technology, the human body and the environment,” Gaharwar said. “The most exciting aspect of this research is its potential applications in robotics, prosthetics, wearable technology, sports and fitness, security systems and entertainment devices.”

Gaharwar's lab invented the E-skin technology, which is described in a report published by Advanced Functional Materials. The paper's lead authors are Drs. Kaivalya Deo '22, a former student of Gaharwar who is currently employed as a scientist at Axent Biosciences, and Shounak Roy, a former Fulbright Nehru doctoral fellow in Gaharwar's lab.

Read more European WEAFING Project - Haptic Sensations by Textile Muscles

The development of robust materials that can replicate human skin's elasticity, incorporate bioelectrical sensing capabilities, and use fabrication techniques appropriate for wearable or implantable devices are obstacles in the process of creating E-skin.

“In the past, the stiffness of these systems was too high for our body tissues, preventing signal transduction and creating mechanical mismatch at the biotic-abiotic interface,” Deo said. “We introduced a ‘triple-crosslinking’ strategy to the hydrogel-based system, which allowed us to address one of the key limitations in the field of flexible bioelectronics.”

Because hydrogels can reduce viscosity under shear stress during E-skin synthesis, making handling and manipulation easier, using nanoengineered hydrogels tackles some of the difficult aspects of E-skin development during 3D printing. According to the team, this property makes it easier to build intricate 2D and 3D electronic structures, which is crucial for simulating the complex architecture of human skin.

Text Link

February 2024: Empowering Visually Impaired with GUIDI

AI Guided transforms lives with GUIDI, an advanced AI navigation companion.

In the ever-evolving landscape of artificial intelligence, AI Guided is proving to be a pioneer, shaping the future for people with visual impairments. The founders were motivated by watching visually impaired people navigate using canes and relying on the shoulders of others. Recognizing a significant gap in accessible and user-friendly AI solutions, they committed to addressing this need and improving lives.

Inspired by this commitment, AI Guided introduces GUIDI - a revolutionary AI-powered navigation companion designed to improve the autonomy of visually impaired people. GUIDI uses advanced AI technology to scan the environment and guide the user through directional vibrations on obstacle-free paths.

Mission

AI Guided's mission is to build the AI Guiding Ecosystem for the world. By integrating AI and innovative technologies, the company aims to create a global ecosystem that promotes inclusion, independence and well-being for people with visual impairments.

Image credits: AI Guided Ltd.

About AI Guided

Founded in Hong Kong in 2020, AI Guided quickly grew into an award-winning technology startup incubated in the prestigious Hong Kong Science Park program. The company specializes in AI, haptic-reflexive control and environmental visualization, focusing on applications for smart cities, social connectivity and social welfare. At the heart of the company is the development of high-tech assistive platforms and wearable devices for visually impaired and elderly people.

Text Link

Movano Begins Shipping Evie Ring for Women

Digital health startup Movano Health announced it has started shipping its female first wearable.

Movano Health, a pioneer in health technology, announced that its female first wearable, the Evie Ring, has started shipments on January 22, 2024.

"This milestone marks the culmination of an incredible journey of hard work, dedication, and innovation," saidJohn Mastrototaro, CEO of Movano Health. "Getting to this point as anorganization reflects the unwavering commitment of our team and the belief in our vision of better health for all. We can't wait to get Evie rings on fingers."

The Evie Ring is the only smart ring created specifically for women. From its open design to personalized insights that connect the dots between all aspects of your health, every part of the experience is curated for women at every age and stage of life.

Movano Health successfully showcased the Evie solution at CES Unveiled on January 7, 2024 where it was named a CES Innovation Award Honoree in Wearables and won "Best of CES" accolades from major press outlets.

Rings will ship in the order they were received, and all orders placed before January 19, 2024 are expected to ship out by February 20, 2024. Going forward, the company expects to shortenorder fulfilment times as it continues to ramp commercial production.

Related Health Monitoring Smart Ring with Sleek Design

Evie Ring’s Health Monitoring Features

  • Vital Metrics on Demand. Accurately measure your critical vitals including Heart Rate and SpO₂ to get an on-demand understanding of your health.
  • Menstrual Cycle. Track your period and menstrual symptoms to better understand your ovulation timing and estimate your fertile windows.
  • Sleep Quality. Identify ways to get a more restful sleep with detailed analysis of your sleep cycles and overnight health vitals.
  • Activity Tracking. Get a comprehensive understanding of your activity levels throughout the day with workout logs and continuous activity tracking.

About Movano Health  

Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives.

Text Link

Wellysis ECG Patch Hits US, Indian Markets

Digital healthcare innovator Wellysis is securing strategic partnerships.

Digital healthcare innovator Wellysis is making waves in the global market with its revolutionary electro cardiogram (ECG) monitoring solution, 'S-Patch,' securing strategic partnerships and distribution deals to propel its entry into the lucrative US and Indian markets.

Wellysis inked a significant supply agreement with a leading US provider of ECG services in November 2023, paving the way for S-Patch distribution across three important states: Texas, Arizona, and Louisiana, with the rollout starting in Texas. The initial deployment of 1,000 devices in late January marks the beginning of a two-year supply commitment, solidifying Wellysis's presence in the world's largest ECG market,which holds a share of over 60% of the total market.

To fuel its US ambitions, Wellysis strategically established a subsidiary in Houston, Texas, through the Johnson & Johnson Innovation Laboratories (JLABS) and continues to forge partnerships for further expansion beyond the central region.

Additionally, Wellysis partnered with Dozee, a prominent bed monitoring solutions provider based in India, in October 2023. Following a successful product launch event in New Delhi, Wellysis is poised to integrate and supply S-Patch devices to 50,000 of Dozee's hospital beds starting in January.

Related Gel-FreeECG Sensor Monitors Heart Health

"The US and India offer unparalleled opportunities for Wellysis," remarked Young Juhn, CEO of Wellysis."With these strategic partnerships, we're confident in S-Patch's success.Our focus is on showcasing S-Patch's versatility through diverse use cases, from remote patient monitoring to hospital bed integration."

About Wellysis

Wellysis is a digital healthcare company dedicated to revolutionizing patient care through innovative ECG monitoring solutions. Its flagship product, S-Patch, is a user-friendly, wearable ECG monitor that provides real-time data and advanced analysis, empowering clinicians and patients alike.

Text Link

New Partnership for Remote Patient Monitoring

Patients in the One Brooklyn Health system will now have access to around-the-clock care.

Brooklyn New York residents now have access to 24/7, personalized healthcare with the addition of remote patient monitoring. Made possible by a partnership between One Brooklyn Health, CAIN Health and CyberMed Health, patients in the One Brooklyn Health system will now have access to around-the-clock care with wearable devices that monitor vitals from the comfort of their home.

"The technology exists now to observe and record health vitals in real-time, alerting medical professionals immediately to any abnormalities or concerns," said Scott Cain, CEO of CAIN Health. "This medical grade equipment, not only can improve health outcomes, but it can also reduce emergency room activity and hospital readmissions, saving busy and stretched thin hospitals and health systems like One Brooklyn Health, much needed resources."

Related Medtronicand Cosmo Partner Up for AI-driven Care

Launched in September of last year, remote patient monitoring is available at no out-of-pocket cost to patients.

"We strive to provide the best care to our patients," said Dr. Sandra Scott, Interim CEO One Brooklyn Health. "Allowing us to continue the quality of care and the connection to our talented team of medical professionals after patients leave the hospital is incredible. It is the future, and we are fortunate to be able to adopt this technology advancement for our community."

CAIN Health has worked with hospital systems across the country to incorporate remote patient monitoring, saving them millions of dollars in hospital readmissions and unnecessary ER visits.

"In busy metropolitan cities, like Brooklyn, remote patient monitoring eases the burden on both the patient and the healthcare providers," continued Scott. "It not only help simprove the quality of care, but it also gives the patient peace of mind without needing to venture from their home."

ABOUT ONE BROOKLYN HEALTH

Established in 2016, One Brooklyn Health, Inc (OBH) aims to enhance and preserve healthcare services in Central Brooklyn and East Brooklyn. Comprised of Interfaith Medical Center (IMC), Brookdale Hospital Medical Center (BHMC), and Kingsbrook Jewish Medical Center (KJMC),OBH is committed to delivering the highest quality and widest range of healthcare services to the community. With a comprehensive network of primary, behavioral health, pediatric, geriatric, sickle cell, podiatry, and maternal health services, OBH strives to meet various healthcare needs. Additionally, OBH operates Schulman S. Schachne Institute for Nursing and Rehabilitation at Brookdale and Rutland Nursing Home at Kingsbrook Jewish Medical Center, along with senior citizen housing at Arlene and David Schlang Pavilion at Brookdale

ABOUT CAIN HEALTH

CAIN Health was formed in 1999 by Wm. Scott Cain to provide revenue recovery and management services to hospitals and physicians across the country. Over the years CAIN Health has helped Providers recover and save tens of millions of dollars through their unique approach to Revenue Cycle Management. CAIN Health offers a full range of services to Hospitals and Health Systems throughout the nation.

Text Link

Migraine Treatment Wearable Approved in Japan

Japanese Ministry of Health, Labor and Welfare (MHLW) has approved neuromodulation migraine device.

Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, announces the approval of its neuromodulation device, Relivion, by the Japanese Ministry of Health, Labor and Welfare (MHLW). This approval marks a historic moment for Neurolief and its partner Sawai Pharmaceutical Co., Ltd, as Relivion becomes the first neuromodulation device approved in Japan for at-home use in the acute treatment of migraine.

Relivion is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and trigeminal nerve branches in the head, effectively modulating brain networks associated with debilitating migraine headaches. The system is complemented by a state-of-the-art patient mobile appand a physician interface featuring cloud-enabled data-tracking capabilities, allowing seamless AI integration and enabling remote patient monitoring.

Marketing efforts for Relivion will be led by Sawai Pharmaceutical Co., Ltd, which have entered into an exclusive partnership agreement with Neurolief for development and commercialization of Relivion for migraine and depression indications in Japan.

Scott Drees, CEO of Neurolief, expressed great enthusiasm for the MHLW approval, emphasizing the profound impact this decision will have on the millions of migraine patients in Japan. Heunder scored this achievement as a pivotal step in realizing Neurolief's mission of bringing its pioneering neurotechnology to individuals globally.

Related Positive Results for Theranicas Neuromodulation Device

Motohiko Kimura, President at Sawai pharmaceutical, emphasized the company's unwavering dedication to prioritizing patients through Sawai's corporate philosophy of 'Always Putting Patients First'. This commitment reflects Sawai's strong resolve to contribute to healthier lives. With the upcoming introduction of the Relivion neuromodulation system in Japan, Sawai aims to elevate the landscape of acute migraine treatment options which is currently limited primarily to drug therapy.

About Neurolief

Neurolief is a leading brainneurotechnology company dedicated to enhancing the lives of patients suffering from Neurological and Neuropsychiatric disorders. Comprising experienced professionals with a proven track record in neuroscience, neuromodulation technology and the neurotech devices industry, the company has developed Relivion MG for the treatment of migraine and Relivion DP for Major Depressive Disorder (MDD). These are the world's first and only non-invasive multi-channel brain neuromodulation technologies designed to concurrently stimulate the occipital and trigeminal nerve branches in the head, there by modulating brainnet works associated with migraine and depression. Relivion MG is currently FDA, CE and MHLW approved for the acute treatment of migraine and aims to provide a highly effective alternative to pharmaceutical therapies. The system also includes a patient mobile app and a physicians' interface with cloud-enabled data-tracking features, enabling AI in corporation and remote patient monitoring.The company is actively pursuing FDA and CE mark approvals for the treatment of Major Depressive Disorder (MDD).

Text Link

Supercharge Your Watch with Cutting-Edge Technology

Doublepoint released "Wow Mouse" an App that lets consumers supercharge their Android watches.

Doublepoint Technologies, a leading innovator in gesture detection technology, today released a free app "Wow Mouse" on Play Store that lets consumers supercharge their Android watches with cutting-edge gesture-touch technology and instant Bluetooth connectivity to headsets, phones, tablets, computers and more. The Finnish startup is releasing a new version of its groundbreaking gesture detection algorithm, now compatible with WearOS smartwatches.

Gesture technology leader Doublepoint Technologies with release of “Wow Mouse” on Play Store. The free app lets consumers supercharge their Android smartwatches with cutting-edge gesture-touch technology and instant Bluetooth connectivity to headsets, phones, tablets, computersand more.

"We're not just changing the game —we're rewriting the rules for human-computer interaction with our touch-based gesture tracking. It's a leap forward, delivering a natural and powerful user experience for smartwatches and beyond," said Ohto Pentikäinen, CEO of Doublepoint. "Our algorithm is designed to seamlessly blend with existing products, empowering OEMs to revolutionize user experiences without reinventing the wheel.

Read more Google’s Pixel Watch Can Now Detect Falls

Any consumer, researcher, developer or tinkerer can empower their WearOS smartwatch with Doublepoint to recognizegestures or explore the software.

At this year, Doublepoint unveils the latest iteration of its core software, introducing Human Interface Devicesupport. This advancement in gesture control introduces stationary pinch and hold, a major breakthrough in wrist-based device control, which allows OEMs and developers to offer consumers a more immersive experience combining gesture and touch.

With HID support, any device can identify the app as a "mouse," facilitating seamless integration with most Bluetooth-enabled devices. This opens up new possibilities for intuitive interaction across a wide range of electronic devices.

In conjunction with the software release, Doublepoint is thrilled to announce the opening of preorders for the Doublepoint Evaluation Kit. Designed for companies seeking to embed the Doublepoint gesture detection algorithm, the kit includes a Doublepoint wristband, advanced algorithms and evaluation tools.

Key features of the Doublepoint Kit

  • Advanced Gesture Detection: The algorithm includes pinch and hold and is robust to arm movements, serving crucial applications in augmented reality headset input, accessibility, IoT, one-handed smartwatch control and more.
  • Licensable Software: The software in the Doublepoint Kit is instantly licensable for integration into existing smartwatches, fitness trackers and other smart wristbands.
  • Reference Design: The Doublepoint Kit serves as a reference design, enabling the creation of new device categories, including input wristbands.

Text Link

Pimax Unveils Groundbreaking VR Innovations

Pimax announced it will unveil its latest technological advancements at CES 2024.

Pimax, a leading innovator in the Virtual Reality (VR) industry, announced it will unveil its latest technological advancements.

At an exclusive event for special guests, attendees were privileged to experience the revolutionary 60G AirLink wireless module, paired with Pimax's current flagship product, the Pimax Crystal. The integration of the 60G AirLink with the Crystal's standard eye-tracking feature elevates it to being the world's first ultra-high-definition VR headset with wireless connectivity.

The 60G AirLink, utilizing cutting-edge 60G millimeter wave (mmWave) technology, highly anticipated in the VR domain,ensures high-speed data transmission and low latency, pivotal for videostreaming and immersive VR experiences. It boasts impressive band width androbust anti-interference capabilities, providing users with an unparalleled audiovisual journey and an ultra-realistic VR experience, all free from the constraints of cables. According to Pimax representatives, these groundbreaking products are slated for official release to consumers in the near future.

Related Newly Developed Virtual Reality Medical Training Approach

An exclusive invitation-only demo featured Pimax's next-generation flagship, the groundbreaking 12K-EVTθ (Engineering Verification Test Zero) prototype. This prototype sets a new benchmark in the VR industry with superior specifications such as unmatched resolution and expansive field of view (FOV) and a revolutionary interchangeable optical system.

Besides the new revelations, visitors to the Pimax booth also had numerous opportunities to experience the Pimax Crystalin various highly entertaining settings, including flight simulation rigs, racing rigs, and VR motion capture gloves. Boasting the highest resolution in consumer VR, the Crystal incorporates innovative features like inside-outtracking, eye-tracking, the 60G AirLink wireless module, and glass lenses for optimal visual clarity.

Pimax's booth attracted significant attention from renowned media outlets including Forbes, PC Gamer, IGN, ZDNET, The Daily Beast, CHIP and numerous industry heavy-weights and influencers.

Text Link

New Wireless Magnetic Phone Charger

Ossia and Toyoda Gosei will launch Cota Forever, a new magnetic wireless phone charger at the CES.

Ossia Inc. today announced the launch of its Cota Forever Magnetic Phone Charger to enable wireless charging of mobile Qi2 and MagSafe devices, such as the iPhone or Samsung Galaxy. The charger is powered by Ossia's FCC-approved Cota Real Wireless Power - the patented technology that delivers power at a distance, and without the need for line-of-sight.

The Cota Forever Magnetic Phone Charger, built by a Toyota Group subsidiary, Toyoda Gosei, a global product manufacturer and an Ossia licensing partner, is a lightweight, rectangular device the sizeof half-a-deck of cards. It comes ready out of the box to attach to the back of a Qi2 or MagSafe device and receives wireless power, which it delivers to the device continuously without further user intervention. This enables users to charge their mobile phones without cords, charging pads or plugging into another device safely over the air and at a distance, even while in use or in motion.

The Cota Forever Magnetic Phone Charger has been named a CES 2024 Innovation Awards winner, the seventh time a Cota-powered Ossia innovation has received that honor in the yearly competition. The awards recognize outstanding design and engineering achievements in consumer technology products. Ossia received its most recent recognition in the mobile devices, accessories and apps category.

"Ossia and Toyoda Gosei have been close partners in developing the Cota Technology for the past three years. This award win is one recognition of the multiple products our two companies are building together. Ossia provides Cota Real Wireless Power and Toyoda Goseibrings extensive product and manufacturing expertise," says Doug Stovall, CEO at Ossia. "The Cota Forever phone charger addresses the major painpoint of charging the mobile phone. One of many products coming to market that will make Cota wireless power a ubiquitous global technology."

Read more Motorola’s New Bendable, Wearable Phone

The Cota Forever Magnetic Charger receives power from a Cota transmitter that can be placed into any environment. The receiver initiates the connection by sending a beacon signal to find the transmitter. The transmitter then sends power back in the same path. This back-and-forth between devices and transmitter happens 100 times per second.

"Over several decades, Toyoda Gosei has explored new ways to enrich people's lives with our technology. Our partnership with Ossia is an exciting and momentous example of that," says Shinichiro Fuki, General Manager of New Value Creation and Development Division at Toyoda Gosei. "The Cota wireless power technology will enable a more sustainable and hands-free reality for a world that is increasingly reliant on mobile devices."

About Ossia

Ossia Inc. is leading the world on what is possible with wireless power. Ossia's flagship Cota technology redefines wireless power by safely delivering remote, targeted energy to devices at a distance. Ossia's Cota technology is a patented smart antenna technology that automatically keeps multiple devices charged without any user intervention and enables an efficient and truly wire-free, powered-up world that is always on and always connected. Ossia is headquartered in Redmond, Washington.

Text Link

Chest Drainage System Granted FDA Clearance

FDA 510(k) clearance for the Passio Pump Drainage System for malignant ascites & pleural effusions.

Bearpac Medical, LLC announced that the FDA has granted 510(k) clearance for its Passio Pump Drainage System for the additional indication of peritoneal to provide therapy for malignant ascites in addition to recurrent pleural effusions.

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic malignant ascites as well as recurrent and symptomatic pleural effusions. The Passio pump is attached to an implanted Passio catheter using the disposable collection kit and is activated to begin the evacuation of fluid into the collection bag. The Passio catheter is exclusively designed for use with the Passio collection system. Passio provides flow control throughout the therapy at lower vacuum pressures than competitive devices on the market today.

Read more: New Wearable to Assess Lung Function

"We are very excited for the expanded indication so that we can now offer Passio to more patients dealing with these difficult diagnoses," said Jay Zimmerman, President of Bearpac Medical.

About Bearpac Medical

Bearpac Medical is a privately held medical technology company headquartered in New Hampshire, focused on the development of novel thoracic drainage products to improve the lives of patients experiencing pleural effusions.

Text Link

VR Therapy Reduces Pain Intensity

A VR therapy program reduces pain intensity up to six months later when compared to a dummy app.

According to a study published in JMIR, a Virtual Reality therapy program reduces pain intensity up to six months later when compared to a dummy app.

The RelieVRx system, formerly known as EaseVRx, was utilized in the trial, which was sponsored by AppliedVR, to evaluate the long-term efficacy of the treatment for individuals with chronic lower back pain (CLBP). It was a follow-up to previous studies comparing the immersive eight-week program against a 2D mock experience just after treatment.

188 individuals received surveys from the researchers before, during, and after the treatment period of one, two, three, and six months. Six months following the therapy, they discovered that the VR group had a mean percentage change in pain intensity of -31.3%, while the sham group had a mean percentage change of -15.9%. While 25% of the sham group and more than half of the VR group passed the criterion for moderate clinical meaningfulness, respectively, reports MobiHealthNews.

Only 13.2% of the sham group attained substantial clinical meaningfulness, compared to 38% of the RelieVRx cohort. The VR intervention reduced pain-related disruptions to activity, stress, and sleep, according to the study. While there were statistically significant variations in physical function and sleep disturbance between the two groups, these changes lacked clinical significance.

"Combined, the results support the 6-month analgesic efficacy of a fully automated, 8-week, home-based VR program for CLBP," the study's authors wrote. "Recent meta-analyses of VR noted a lack of high-quality efficacy studies for chronic pain, except for those involving physical rehabilitation programs. To our knowledge, our investigations on the extended efficacy of VR are the first involving home-based pain management without physical rehabilitation."

The study's shortcomings, according to the researchers, include the individuals' modest levels of depressive symptoms and its dependence on self-reported results. Despite being double-blind, the majority of participants were able to determine which group they belonged to, indicating that the blinding may not have been effective.

Read more: Partnership for VR Therapeutic Trial

Additionally, the sample consisted primarily of white female participants with some college education, thus others from different backgrounds might not find it useful. Researchers did, however, look into whether individuals' engagement was impacted by their socioeconomic position (SES).

"While our examination of the impact of SES on user engagement is preliminary and may be subject to selection bias, we found equivalent engagement between lower and higher SES individuals with EaseVRx. These data potentially refute a perception that a high-tech digital treatment, such as VR, may be infeasible in lower SES individuals and suggest that digital therapeutics, like EaseVRx, represent an opportunity to reach CLBP patients in historically underserved areas," the researchers wrote.

Text Link

Ways AI Will Be Used in Healthcare in 2024

Digital health industry leaders revealed where they believe AI will have the biggest impact.

After a notable uptick in AI's use in healthcare in 2023, stakeholders anticipate even more widespread use of the technology in 2024 across a range of industries, from consumer loneliness to physician burnout relief through physician-facing technologies. Digital health industry leaders shared with MobiHealthNews that they believe Artificial Intelligence will have the biggest impact on healthcare in 2024.

Neil Patel, head of new ventures at Redesign Health: "At the enterprise level, uncertainty around OpenAI's future may lead to organizations taking a step back to develop an AI strategy that isn't so dependent on a single platform–analogous to the multi-cloud strategy discussion. From a use case perspective, until more traceability and verification for AI-generated outputs and regulation catches up, AI will be pointed at administrative and operational use cases vs. clinical and patient-facing ones."

Doug Hirsch, Co-founder and Chief Mission Officer at GoodRx: "This year, we saw AI, ChatGPT, and VR dominate tech conversations. And I’m sure we’ll continue to see consumers and the health system embrace these solutions in some way, shape, or form next year. But I really think the industry should prioritize applying the technology that solves our most fundamental healthcare challenges.

That doesn’t necessarily mean we need the flashiest technology. In fact, the shiniest solutions often are not immediately scalable, and therefore, their promise to better our healthcare system lies multiple years down the road. My hope is we’ll see more smart applications of AI that increase transparency within the healthcare system."

Read more: Medtronic and Cosmo Partner Up for AI-driven Care

Kourosh Davarpanah, CEO and Co-founder of Inato: "In 2024, we will see an unusually swift adoption of AI at all levels of the healthcare industry. This trend is already evident in the biopharma industry. Traditionally a slower adopter, biopharma is already using AI at scale from drug discovery to portfolio management, all the way to clinical trial design and delivery."

Matthew Stoudt, Co-founder and CEO of AppliedVR: "We are entering the Cambrian explosion of AI in healthcare. Using algorithms to better respond to individual patients and personalize care will be a new frontier for AI, and in VR, there are opportunities to deliver AI-driven one-to-one and group therapy sessions as well as precision VR therapy based on each person's biofeedback data. I'm excited to see the impact AI will make across the ecosystem."

Amit Khanna, Senior Vice President and General Manager of Health at Salesforce: "My prediction is that generative AI will transform healthcare, fundamentally changing the cost trajectory of the industry. GenAI will be used for a number of things, including creating efficiencies in claim management and summarization, turning unstructured data into insights, and spotting trends/patterns to better predict at-risk patients. It will also be applicable in the life sciences industry, accelerating clinical trials, including the trial recruitment and enrollment process, such as identifying eligible participants and matching them with the right sites to reduce drop off in a clinical trial study."

Text Link

New Partnership to Bring E4 Gaming Headset to EU

VR firm DPVR partnered up with Schenker Technologies to bring DPVR’s E4 to a broader audience.

DPVR, the pioneering force in the Virtual Reality industry, announced a strategic collaboration with Schenker Technologies, a prominent provider of IT and XR hardware and accessories operating throughout Europe. The partnership aims to bring DPVR's gaming headset E4 to a broader audience through Schenker's e-commerce platform.

DPVR has consistently remained at the forefront of the VR device design and manufacturing sector, delivering innovative tethered and wireless VR headsets that cater to diverse industries. From education and training to simulation and entertainment, DPVR’s VR solutions have been transforming the way businesses and organizations engage with immersive technology, reports DPVR.

Schenker Technologies, based in Leipzig, Germany, is renowned for its comprehensive range of IT and XR products and services. With an emphasis on Augmented and Virtual Reality technologies, the company’s expertise spans production, storage, distribution, and expert trilingual customer support. Their locally manufactured, freely configurable laptops and desktop PCs under the brands XMG and SCHENKER have received numerous accolades from industry media for their performance and cutting-edge components.

The e-commerce platform bestware.com, complements its existing product range with a carefully curated selection of top-tier products from leading manufacturers, along with the bestware.com laptop and desktop PC configurator.

By combining their strengths, DPVR and Schenker Technologies aim to make DPVR E4 easily accessible to consumers across Europe. DPVR’s innovative technology, when paired with Schenker’s seamless distribution and support capabilities, is set to revolutionize the virtual reality landscape in the region.

Read more: New Partnership Aims to Detect Brain Disorder Using Virtual Reality

Key Benefits of the Collaboration

  • Expanded Reach: The E4 headset will now be available to a wider European audience through Schenker’s thriving e-commerce platform.
  • Comprehensive Support: Schenker Technologies’ expertise in customer service and support will further enhance the overall VR experience for users, guaranteeing a seamless and satisfying journey with DPVR E4.

“We are thrilled to collaborate with Schenker Technologies to introduce our VR headset E4 to a broader audience in Europe,” said Derek Liu, VP of DPVR. “This partnership signifies a major stride in making immersive technology more accessible and allowing users to explore the endless possibilities of Virtual Reality.”

“We are excited to welcome DPVR to our bestware.com platform,” stated Tom Neubert, Sr. Product Manager XR at Schenker Technologies. “The addition of DPVR E4 aligns perfectly with our commitment to offering the most innovative and sought-after products to our customers, ensuring they have access to the very best in Virtual Reality technology.” With DPVR’s innovative Virtual Reality technology and Schenker Technologies’ established presence in the European market, the collaboration promises to reshape the way people interact with VR content and brings immersive experiences to new heights.

About DPVR

DPVR is an innovative Shanghai-based technology company specializing in VR device design and manufacturing. With a diverse portfolio of tethered and wireless VR headsets, DPVR caters to numerous industries, unlocking transformative solutions for education, training, simulation, and entertainment domains. DPVR proudly provides fully customizable VR solutions tailored to meet the dynamic immersive technology requirements of modern enterprises.

About Schenker Technologies

Schenker Technologies is a Leipzig-based company operating throughout Europe as a provider of IT hardware and accessories, distribution services, and the latest in Augmented and Virtual Reality technologies. With around 120 employees, the company offers a comprehensive range of activities, from production and storage to service, support, and administration. Schenker Technologies prides itself on being an innovative trendsetter, using its distribution experience to provide the European market with the world’s most interesting new technologies and custom solutions.

Text Link

LetinAR to Launch Multiple AR Glasses

The company will release PinTILT lens, Jorjin, Nimo, and other AR glasses in mid-January.

LetinAR Inc., a developer of optical solutions for Augmented Reality (AR) smart glasses, announced that, at the CES 2024 in Las Vegas, USA, to be held between January 9-12, it will be releasing its PinTILT lens, which brings AR optics to the next level and successful commercialization cases with its global customers including Jorjin, Nimo, and others.

As a developer of optical systems for AR smart glasses, LetinAR introduced its PinTILT technology at the CES for the last seven consecutive years. LetinAR drew the attention of global companies as it was recognized for having overcome the performance limitations of the existing AR optical system on the back of its unique and practical technology. LetinAR releases its FrontiAR Pro optical system based on PinTILT technology at CES 2024, which resolves technological barriers and elevates the optical system to the next level.

The strongest feature of the FrontiAR Pro lens is that it overcomes the issue of brightness uniformity, which has been the greatest challenge to existing PinMR (Pin Mirror) AR optical systems. The brightness uniformity, which was previously limited, has been improved, thereby enhancing performance by approximately three times. On top of that, the image quality, an existing strength, has been further improved so that it can be easily worn like regular glasses.

At CES 2024, visitors can experience an ultra-high definition, immersive AR demonstration, which is developed based on the PinTILT AR optical system. The global customers of LetinAR, mainly Jorjin, a leading XR device manufacturer with more than ten years of experience, introduce J8L Glasses, optimized for spatial experiences based on the LetinAR FrotinAR Pro (Formerly B42) optical system. Nimo, the developer of the World's First Spatial Computer for Productivity, launches Nimo One, also equipped with the LetinAR FrotinAR Pro optical system. Additionally, more customers of LetinAR from America and Asia will launch their successful productization cases onsite. All visitors are welcome to experience all the glasses.

The company and its customers plan to exhibit interactive, responsive content that provides the first-hand experience of immersive spatial content. Users may also test demonstrations in the form of goggles, giving users the experience of wearing helmets such as Ironman's Jarvis or those worn by F-35 fighter plane pilots. By combining the Generative AI function, Nimo is planning to demonstrate Nimo Glasses, Nimo Core, and OS which are designed for Spatial Productivity and fit in our Pocket. Also receiving the spotlight is Jorjin's J8L Glasses, which enables an immersive Metaverse experience utilizing 9-Axis IMU and AI recognition software.

Jaehyeok Kim, CEO of LetinAR, says, "It was LetinAR's strong technological base that enabled us to not only overcome the limitations of the existing AR optical system but also to overcome the vertical viewing angle issue, which has been regarded as a major technological challenge", and added that "It is glad to demonstrate diverse smartglasses launched by our global customers all around the world at the CES 2024."

Lerdah Wang, General Manager of Jorjin, says, "We're delighted to say that Jorjin's J8L AR smart glasses powered by outstanding PinTILT technology from LetinAR can bring users an incredible experience in special field applications.", and "The slim design and lightweight can fit for wearing for a long time. With gesture recognition, the human-computing interaction is intuitive and can be used in a wide range of fields such as smart manufacturing, smart showroom, city touring, immersive collaboration and education, and smart medical applications for augmented upgrading and digital transformation."

About LetinAR

Founded in 2016, LetinAR, a company operating in the AR scene, presents a new paradigm-changing technology - PinTILT lens. This technology was developed mainly to redress common failings found in current products; heavy and expensive hardware, and deficient functions that inhibit the construction of real eyeglasses-shaped designs and render wearability and usability mediocre at best. Since its inception in 2016, LetinAR with PinTILT technology has been in the global spotlight during the previous CES and MWC.

Text Link

New Biocompatible Ink for Heart Valve Repair

Biocompatible ink solidifies into different 3D shapes and structures by absorbing ultrasound waves.

Engineers at Duke University and Harvard Medical School have developed a biocompatible ink that solidifies into different 3D shapes and structures by absorbing ultrasound waves. Because it responds to sound waves rather than light, the ink can be used in deep tissues for biomedical purposes ranging from bone healing to heart valve repair.

The uses of 3D-printing tools are ever-increasing. Printers create prototypes of medical devices, design flexible, lightweight electronics, and even engineer tissues used in wound healing. However, many of these printing techniques involve building the object point-by-point in a slow and arduous process that often requires a robust printing platform, reports Duke University.

To circumvent these issues over the past several years, researchers developed a photo-sensitive ink that responds directly to targeted beams of light and quickly hardens into a desired structure. While this printing technique can substantially improve the speed and quality of a print, researchers can only use transparent inks for the prints, and biomedical purposes are limited, as light can’t reach beyond a few millimeters deep into the tissue.

Now, Y. Shrike Zhang, associate bioengineer at Brigham and Women’s Hospital and associate professor at Harvard Medical School, and Junjie Yao, associate professor of biomedical engineering at Duke, have developed a new printing method called deep-penetrating acoustic volumetric printing, or DVAP, that resolves these problems.

This new technique involves a specialized ink that reacts to sound waves rather than light, enabling them to create biomedically useful structures at unprecedented tissue depths.

Read more: Silicone 3D Printing Paving the Way for Soft Robotics and Wearables

"DVAP relies on the sono-thermal effect, which occurs when soundwaves are absorbed and increase the temperature to harden our ink," explained Yao, who designed the ultrasound printing technology for DVAP. "Ultrasound waves can penetrate more than 100 times deeper than light while still spatially confined, so we can reach tissues, bones, and organs with high spatial precision that haven’t been reachable with light-based printing methods."

The first component of DVAP involves a sonicated ink, called sono-ink, that is a combination of hydrogels, microparticles, and molecules designed to specifically react to ultrasound waves. Once the sono-ink is delivered into the target area, a specialized ultrasound printing probe sends focused ultrasound waves into the ink, hardening portions of it into intricate structures. These structures can range from a hexagonal scaffold that mimics the hardness of bone to a bubble of hydrogel that can be placed on an organ.

"The ink itself is a viscous liquid, so it can be injected into a targeted area fairly easily, and as you move the ultrasound printing probe around, the materials in the ink will link together and harden," said Zhang, who designed the sono-ink in his lab at the Brigham. "Once it’s done, you can remove any remaining ink that isn’t solidified via a syringe."

"Because we can print through tissue, it allows for a lot of potential applications in surgery and therapy that traditionally involve very invasive and disruptive methods," said Yao. "This work opens up an exciting new avenue in the 3D printing world, and we’re excited to explore the potential of this tool together."

Text Link

Sonar Technology Tracks Body Movements in 3D

PoseSonic is the latest sonar-equipped wearable from Cornell University’s SciFi lab.

A variation of sonar technology – in miniature form, developed by Cornell University researchers – is proving a game-changer in wearable body-sensing technology.

PoseSonic consists of off-the-shelf eyeglasses outfitted with micro sonar that can track the wearer’s upper body movements in 3D through a combination of inaudible sound waves and artificial intelligence (AI). With further development, researchers believe it could enhance augmented reality (AR) and virtual reality (VR) and track detailed physical and behavioral data for personal health, reports EurekaAlert.

“We’re the first research group using inaudible acoustics and AI to track body poses through a wearable device,” said Cheng Zhang, assistant professor of information science. “By integrating cutting-edge AI into low-power, low-cost, and privacy-conscious acoustic sensing systems, we use less instrumentation on the body, which is more practical, and battery performance is significantly better for everyday use.”

PoseSonic has two pairs of tiny microphones and speakers – each about the diameter of a pencil – attached to the hinges of eyeglasses. The speakers emit inaudible sound waves that bounce off the upper body and back up to the microphones, generating an echo profile image. This image is then fed into PoseSonic’s machine-learning algorithm, which estimates the body pose with near-perfect accuracy. And unlike other data-driven, wearable pose-tracking systems, PoseSonic functions well without an initial training session with the user, the researchers said.

Read more: Wearable Utilizes Temperature for Wellness Applications

The system can estimate body movements made at nine body joints, including the shoulders, elbows, wrists, hips, and nose, which is useful to estimate head positioning, researchers mentioned.

The technology is a major step up from existing wearable devices that often require a mini video camera, which isn’t always practical. Current wearables with video cameras also require significant battery power, the researchers said. Acoustic sensing requires minimal power – 10 times less than a wearable camera. Because of this, the technology makes for a much smaller and unobtrusive wearable.

Further, there’s much less privacy risk with sonar. “A wearable video camera poses privacy risks for anyone in the wearer’s vicinity,” said Saif Mahmud, a doctoral student in the field of information science. “Our solution: Let’s put a little inaudible acoustic field around us that can track our body’s movement while also respecting other people’s privacy.”

This research is supported by the National Science Foundation.

No items found.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.